☆ 4.7 Meeting Abstract

Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 33, Issue 3, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2015.33.3_suppl.344

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, General & Internal

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric A. Collisson, Dvir Aran

Summary: This study compared the two common first-line treatments for metastatic adenocarcinoma of the pancreas, FOLFIRINOX and gemcitabine plus nab-paclitaxel, and found that FOLFIRINOX was associated with improved overall survival and fewer posttreatment complications.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Multidisciplinary Sciences

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

Biyun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xichun Hu

Summary: Platinum in combination with gemcitabine is recommended for the treatment of metastatic triple-negative breast cancer. In a randomized controlled trial, nab-paclitaxel/cisplatin was compared with gemcitabine/cisplatin in mTNBC patients. The study found that nab-paclitaxel/cisplatin significantly improved progression-free survival, objective response rate, and overall survival compared to gemcitabine/cisplatin. However, there were higher incidences of neuropathy in the nab-paclitaxel/cisplatin group and thrombocytopenia in the gemcitabine/cisplatin group.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Oncology

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

J. Randolph Hecht, Sara Lonardi, Johanna Bendell, Hao-Wen Sim, Teresa Macarulla, Charles D. Lopez, Eric Van Cutsem, Andres J. Munoz Martin, Joon Oh Park, Richard Greil, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, Yong Lin, Sujata Rao, Baek-Yeol Ryoo

Summary: The study found that adding PEG to FOLFOX did not improve efficacy in patients with metastatic pancreatic ductal adenocarcinoma, and the safety profiles of the two treatment arms were similar.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine

Francesco Di Costanzo, Federica Di Costanzo, Lorenzo Antonuzzo, Ernesto Mazza, Elisa Giommoni

Summary: Choosing the best first-line treatment for metastatic pancreatic cancer is crucial in improving survival rate and quality of life. FOLFIRINOX and Nab-p plus Gem have been recognized as the most effective treatment regimens. FOLFIRINOX shows better efficacy but higher toxicity.

CANCERS (2023)

Add to Collection

Article Oncology

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Mrinal M. Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Richard F. Riedel, Silvia Stacchiotti, Elizabeth T. Loggers, Kristen N. Ganjoo, Axel Le Cesne, Antoine Italiano, Xavier Garcia Del Muro, Melissa Burgess, Sophie Piperno-Neumann, Christopher Ryan, Mary F. Mulcahy, Charles Forscher, Nicolas Penel, Scott Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean-Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K. Schwartz, James L. Chen, Hari Deshpande, Elizabeth J. Davis, Garth Nicholas, Stefan Groeschel, Helen Hatcher, Florence Duffaud, Antonio Casado Herraez, Roberto Diaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian Meyer, Margaret von Mehren, Brian A. Van Tine, Katharina Gotze, Filomena Mazzeo, Alexander Yakobson, Aviad Zick, Alexander Lee, Anna Estival Gonzalez, Andrea Napolitano, Mark A. Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben-Shahar, Dane R. Van Domelen, Christopher J. Walker, Hua Chang, Yosef Landesman, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Steven Attia

Summary: The clinical benefit of Selinexor in patients with advanced DD-LPS has been evaluated. The results showed that Selinexor improved PFS and time to next treatment compared to placebo.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study

Mitesh J. Borad, Li-Yuan Bai, Donald Richards, Kabir Mody, Joleen Hubbard, Sun Young Rha, John Soong, Daniel McCormick, Emmett Tse, Daniel O'Brien, Ahmad Bayat, Daniel Ahn, S. Lindsey Davis, Joon Oh Park, Do-Youn Oh

Summary: This study investigates the safety and efficacy of silmitasertib in combination with gemcitabine and cisplatin for the treatment of cholangiocarcinoma. The results show promising preliminary evidence of efficacy for the first-line treatment of locally advanced/metastatic cholangiocarcinoma.

HEPATOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence

Juraj Prejac, Dora Tomek Hamzic, Niksa Librenjak, Irma Gorsic, Domina Kekez, Stjepko Plestina

Summary: In first-line treatment of metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine showed improved overall survival and progression-free survival compared to gemcitabine alone. Elderly patients, patients with poorer performance, higher metastatic burden, and liver involvement benefited the most from combination therapy.

MEDICINE (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy

Seo Yeon Kim, Min Jeong Jo, Moon Sup Yoon, Chae Eun Jin, Yu Been Shin, Jae Min Lee, Hee Ji Shin, Joon Gyo Oh, Jae Min Cho, Hyunjun Kim, Hyunjin Park, Yong-Won Choi, Chun-Woong Park, Jin-Seok Kim, Dae Hwan Shin

Summary: This study developed a drug delivery strategy for pancreatic ductal adenocarcinoma using a thermosensitive gel, which successfully achieved controlled release of drugs based on the researchers' tolerance settings. The gel consisted of gemcitabine (GEM) and the mammalian TOR (mTOR) inhibitor rapamycin (RAPA), demonstrating good cytotoxicity and anti-tumor effects in in vitro and in vivo experiments.

JOURNAL OF CONTROLLED RELEASE (2023)

Add to Collection

Article Oncology

PhaseIIstudy evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE1)

Eric Assenat, Laurent Mineur, Caroline Mollevi, Evelyne Lopez-Crapez, Catherine Lombard-Bohas, Emmanuelle Samalin, Fabienne Portales, Thomas Walter, Helene de Forges, Marie Dupuy, Florence Boissiere-Michot, Alexandre Ho-Pun-Cheung, Marc Ychou, Thibaut Mazard

Summary: The combination of gemcitabine, trastuzumab, and erlotinib showed promising efficacy in terms of disease control, progression-free survival (PFS), and overall survival (OS) for patients with metastatic pancreatic cancer. The treatment was well tolerated with manageable toxicities, suggesting the need for further evaluation in a larger study comparing it to the standard regimen.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor

Angelika Bickel, Stefan Diem, Lukas Flatz, Bjorn Stinn, Marco Siano

Summary: Standard treatment for advanced melanoma, including dacarbazine and interleukin-2, has low response rates and significant toxicity. New treatments such as immunotherapy and targeted therapy for patients with a BRAF mutation have shown promise, but options for patients with a NRAS mutation are limited.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers

Boya Li, Yu Feng, Qiaoyun Hou, Yan Fu, Yongzhang Luo

Summary: This study found that high expression of antigen peptide transporter 1 (TAP1) is associated with MEKi resistance in pancreatic cancer. Suppression of TAP1 significantly increases sensitivity of pancreatic cancer cells to MEKi, reduces tumor growth, and attenuates inhibition of the KRAS signaling pathway. TAP1 may serve as a marker for predicting patient response to MEKi, and combining TAP1 suppression with MEKi may be a novel therapeutic strategy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

Esther N. Pijnappel, Nienke P. M. Wassenaar, Oliver J. Gurney-Champion, Remy Klaassen, Koen van der Lee, Marjolein C. H. Pleunis-van Empel, Dick J. Richel, Marie C. Legdeur, Aart J. Nederveen, Hanneke W. M. van Laarhoven, Johanna W. Wilmink

Summary: The combination of LDE225 with gemcitabine and nab-paclitaxel was well-tolerated and effective in patients with metastatic PDAC, especially in those with poor baseline tumor perfusion. These results suggest a potential clinical benefit of this combination therapy in patients who have received prior FOLFIRINOX treatment.

CANCERS (2021)

Add to Collection

Article Oncology

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

Simon J. Crabb, Gareth Griffiths, Ellice Marwood, Denise Dunkley, Nichola Downs, Karen Martin, Michelle Light, Josh Northey, Sam Wilding, Amy Whitehead, Emily Shaw, Alison J. Birtle, Amit Bahl, Tony Elliott, Charlotte Westbury, Santhanam Sundar, Angus Robinson, Satinder Jagdev, Satish Kumar, Claire Rooney, Carolina Salinas-Souza, Christine Stephens, Vincent Khoo, Robert J. Jones

Summary: Capivasertib as a pan-AKT inhibitor did not prolong cPFS in mCRPC patients, but the observed OS result shows potential and requires prospective validation in future studies.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study

Martin Salzmann, Johannes Pawlowski, Carmen Loquai, David A. Rafei-Shamsabadi, Frank Meiss, Selma Ugurel, Dirk Schadendorf, Friedegund Meier, Alexander H. Enk, Jessica C. Hassel

Summary: This retrospective, multi-centre study evaluated the clinical course of patients with advanced NRAS-mutated melanoma treated with MEK inhibitors (MEKi) in German cancer centres. The results showed that MEKi can stabilize the disease course but expectations regarding ongoing tumor response should be tempered.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Multidisciplinary Sciences

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer

Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa

Summary: This study investigated the survival and efficacy of different chemotherapy regimens in patients with metastatic pancreatic cancer. The results showed that second-line chemotherapy was associated with longer overall survival compared to best supportive care. However, there was no significant difference in survival between combination chemotherapy and mono chemotherapy in the second-line treatment.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

Philipp K. Haber, Florian Castet, Miguel Torres-Martin, Carmen Andreu-Oller, Marc Puigvehi, Maeda Miho, Pompilia Radu, Jean-Francois Dufour, Chris Verslype, Carolin Zimpel, Jens U. Marquardt, Peter R. Galle, Arndt Vogel, Melanie Bathon, Tim Meyer, Ismail Labgaa, Antonia Digklia, Lewis R. Roberts, Mohamed A. Mohamed Ali, Beatriz Minguez, Davide Citterio, Vincenzo Mazzaferro, Fabian Finkelmeier, Joerg Trojan, Burcin Ozdirik, Tobias Mueller, Moritz Schmelzle, Anthony Bejjani, Max W. Sung, Myron E. Schwartz, Richard S. Finn, Swan Thung, Augusto Villanueva, Daniela Sia, Josep M. Llovet

Summary: This study analyzed tumor samples from patients with advanced hepatocellular carcinoma (aHCC) treated with anti-PD1 and identified interferon signaling and major histocompatibility complex-related genes as key molecular features of HCCs responding to anti-PD1. The researchers developed an 11-gene signature that can predict treatment response and survival in frontline aHCC patients.

GASTROENTEROLOGY (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/ NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study

Elin Pauwels, Frederik Cleeren, Terence Tshibangu, Michel Koole, Kim Serdons, Lennert Boeckxstaens, Jeroen Dekervel, Timon Vandamme, Willem Lybaert, Bliede Van den Broeck, Annouschka Laenen, Paul M. Clement, Karen Geboes, Eric Van Cutsem, Sigrid Stroobants, Chris Verslype, Guy Bormans, Christophe M. Deroose

Summary: A recent multicenter trial demonstrated that 18F-AlF-OC, as a radiotracer, is noninferior to 68Ga-DOTA-SSA in somatostatin receptor imaging for neuroendocrine tumor patients. This study provides scientific evidence for the clinical application of 18F-AlF-OC.

JOURNAL OF NUCLEAR MEDICINE (2023)

Add to Collection

Review Endocrinology & Metabolism

Closing spontaneous portosystemic shunts in cirrhosis: Does it make sense? Does it work? What does it take?

Wim Laleman, Michael Praktiknjo, Mette Munk Lauridsen, Lawrence Bonne, Emma Vanderschueren, Chris Verslype, Aleksander Krag, Jonel Trebicka, Geert Maleux

Summary: Spontaneous portosystemic shunts are often overlooked as a cause of hepatic encephalopathy associated with cirrhosis. They are considered as radiological biomarkers of clinically significant portal hypertension and have a clinical impact on complications related to portal hypertension. Interventional radiology embolization is a direct method to target these shunts.

METABOLIC BRAIN DISEASE (2023)

Add to Collection

Review Oncology

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma

Cedric Brackenier, Lisa Kinget, Sarah Cappuyns, Chris Verslype, Benoit Beuselinck, Jeroen Dekervel

Summary: Hepatocellular carcinoma (HCC) is a prevalent cancer with a high mortality rate. The combination of an antiangiogenic drug and an immune checkpoint inhibitor has become the new standard of care for advanced HCC. This review discusses the mode of action, clinical efficacy, and biomarker research for both drug classes and the combination therapy. It also highlights the synergy between the two drugs and provides insights into the underlying immunoreactive tumor microenvironment.

CANCERS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

Can G. Leineweber, Miriam Rabehl, Anne Pietzner, Nadine Rohwer, Michael Rothe, Maciej Pech, Bruno Sangro, Rohini Sharma, Chris Verslype, Bristi Basu, Christian Sengel, Jens Ricke, Nils Helge Schebb, Karsten-H. Weylandt, Julia Benckert

Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer death, and the medical treatment options are limited. The multikinase inhibitor sorafenib has been widely used for systemic therapy in advanced HCC. This study shows that sorafenib affects the levels of polyunsaturated fatty acids (PUFA)-derived epoxygenated metabolites, indicating that specific supplementation with DHA could increase levels of the epoxy compound 19,20-EDP with potential anti-tumor activity in HCC patients receiving sorafenib therapy.

FRONTIERS IN PHARMACOLOGY (2023)

Add to Collection

Article Ecology

The effect of hypoxia on Daphnia magna performance and its associated microbial and bacterioplankton community: A scope for phenotypic plasticity and microbiome community interactions upon environmental stress?

Manon Coone, Isabel Vanoverberghe, Shira Houwenhuyse, Chris Verslype, Ellen Decaestecker

Summary: The depletion of oxygen due to increased stratification and decreased solubility is a significant chemical change in aquatic ecosystems under global environmental change, leading to increased exposure of aquatic organisms to hypoxic conditions. Understanding the effects of hypoxia on key ecological species and their microbial communities is crucial for predicting the response of aquatic communities to this environmental disturbance. In this study, the (sub-)lethal effects of hypoxia on Daphnia, a keystone species in freshwater ecosystems, were examined, along with the potential role of the microbial community in the phenotypic switch and tolerance to hypoxia. The results showed phenotypic plasticity in Daphnia performance traits, as well as changes in species richness and community composition of the microbial community, suggesting the importance of the microbiome in phenotypic plasticity and hypoxia tolerance in Daphnia.

FRONTIERS IN ECOLOGY AND EVOLUTION (2023)

Add to Collection

Article Oncology

A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system

A. Coolbrandt, H. Tobback, R. Govaerts, L. Vandezande, M. Vinckx, A. Laenen, H. Wildiers, C. Verslype, J. Dekervel, F. Van Herpe, E. Van Cutsem

Summary: This study aimed to evaluate the effect of hand/foot-cooling on oxaliplatin-induced peripheral neuropathy (OIPN). The results showed that the use of cooling devices significantly reduced the incidence of OIPN and improved acute OIPN symptoms. Patients generally felt comfortable with the intervention.

ESMO OPEN (2023)

Add to Collection

Article Gastroenterology & Hepatology

Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

Alexey Surov, Maximilian Thormann, Mattes Hinnerichs, Max Seidensticker, Ricarda Seidensticker, Osman Oecal, Kerstin Schuette, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Irene Bargellini, Roberto Iezzi, Thomas Berg, Heinz J. Kluempen, Julia Benckert, Antonio Gasbarrini, Holger Amthauer, Bruno Sangro, Peter Malfertheiner, Jazan Omari, Andreas Wienke, Jens Ricke, Maciej Pech

Summary: This study aimed to assess the impact of body composition on survival in patients with HCC treated with sorafenib or SIRT and sorafenib, and the results showed that body composition parameters were not associated with overall survival in advanced HCC patients.

HEPATOLOGY COMMUNICATIONS (2023)

Add to Collection

Article Immunology

Rituximab and improved nodular regenerative hyperplasia-associated non-cirrhotic liver disease in common variable immunodeficiency: a case report and literature study

Willem Roosens, Frederik Staels, Sien Van Loo, Stephanie Humblet-Baron, Isabelle Meyts, Hadewijch De Samblanx, Chris Verslype, Hannah van Malenstein, Schalk van der Merwe, Wim Laleman, Rik Schrijvers

Summary: Common variable immunodeficiency (CVID) associated liver disease is an underrecognized and poorly studied non-infectious complication that lacks an established treatment. However, our case and literature review suggest a potential beneficial effect of rituximab for treating liver complications, which warrants further research.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Meeting Abstract Endocrinology & Metabolism

Characteristics and management of high grade gastroenteropancreatic neuroendocrine neoplasms - A Belgian retrospective analysis from the DNET & NETwerk registry

O. Islam, K. Sarti, C. Verslype, J. L. Van Laethem, Hassan R. Kalantari, J. Janssens, A. Hendlisz, W. Lybaert, M. Peeters, I Borbath, T. Vandamme

JOURNAL OF NEUROENDOCRINOLOGY (2023)

Add to Collection

Meeting Abstract Endocrinology & Metabolism

Adaptive immunosuppressive resistance mechanisms towards antiangiogenic immunotherapies revealed in a pancreatic neuroendocrine tumor (PNET) model

John D. Robbert, M. Guyot, T. Killian, C. Verslype, D. Lambrechts, G. Bergers

JOURNAL OF NEUROENDOCRINOLOGY (2023)

Add to Collection

Meeting Abstract Endocrinology & Metabolism

Intra-individual comparison of 68Ga-DOTATATE PET/CT and PET/MR

Bidakhvidi N. Ahmadi, G. Lens, V. Vandecaveye, S. Grauwels, W. Deckers, J. Dekervel, C. Verslype, E. van Cutsem, M. Koole, K. Goffin, K. van Laere, C. M. Deroose

JOURNAL OF NEUROENDOCRINOLOGY (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

PD1-negative CD45RA effector-memory CD8 T-cells are essential for response to checkpoint inhibition in advanced hepatocellular carcinoma

Sarah Cappuyns, Gino Philips, Vincent Vandecaveye, Bram Boeckx, Rogier Schepers, Thomas Van Brussel, Ingrid Arijs, Aurelie Mechels, Ayse Bassez, Francesca Lodi, Joris Jaekers, Halit Topal, Baki Topal, Orian Bricard, Junbin Qian, Eric Van Cutsem, Chris Verslype, Diether Lambrechts, Jeroen Dekervel

JOURNAL OF HEPATOLOGY (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNA-sequencing-derived gene signatures

Sarah Cappuyns, Marta Pique-Gili, Roger Esteban-Fabro, Gino Philips, Roser Pinyol, Vincent Vandecaveye, Jordi Abril-Fornaguera, Philipp Haber, Chris Verslype, Eric Van Cutsem, Diether Lambrechts, Augusto Villanueva, Jeroen Dekervel, Josep Llovet

JOURNAL OF HEPATOLOGY (2023)

Add to Collection

Article Surgery

Transition from laparoscopic to robotic liver surgery: clinical outcomes, learning curve effect, and cost-effectiveness

M. D'Hondt, A. Devooght, E. Willems, D. Wicherts, C. De Meyere, I Parmentier, A. Provoost, H. Pottel, C. Verslype

Summary: This study evaluates the short-term outcomes and cost differences of robotic liver surgery (RLS) compared to laparoscopic liver surgery (LLS). The findings indicate that RLS has comparable short-term outcomes to LLS but with shorter operative time, lower intraoperative blood loss, and shorter hospital stay. The cost analysis also shows that RLS is more cost-effective compared to LLS.

JOURNAL OF ROBOTIC SURGERY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.